GERARD SOULA

About GERARD SOULA

Gérard Soula is a key figure in the history of Adocia, the French listed biotechnology company focused on diabetes, obesity, and broader metabolic diseases. He co-founded Adocia in 2005 with his two sons, Olivier and Rémi Soula, and played a decisive role in shaping the company’s early strategy around innovative medicines and differentiated formulation technologies. Adocia’s corporate materials describe the company’s origins as a family entrepreneurial project built on a clear ambition: to develop innovative medicines for everyone, everywhere. Throughout his journey at Adocia, Gérard Soula embodied the profile of a scientist-entrepreneur. The company emphasizes that the three founders are highly trained scientists with doctorates in polymer science and significant experience in protein formulation. This scientific foundation helped define Adocia’s identity and supported the development of its proprietary BioChaperone® technology, which became central to the company’s innovation platform. His contribution therefore went beyond governance: he was part of the original intellectual and industrial architecture of the business. On the governance side, Gérard Soula represented continuity, long-term vision, and family stewardship. In May 2023, Adocia announced that Olivier Soula would become Chief Executive Officer, while Gérard Soula’s mandate as Chairman of the Board was renewed. In June 2025, Adocia disclosed that Gérard Soula would step down from his positions as Chairman, with the termination of his functions becoming effective on February 23, 2026, due to the statutory age limit. The board then appointed Stéphane Boissel as his successor. These milestones show that Gérard Soula remained at the center of Adocia’s governance for two decades, helping guide the company through growth, partnerships, and its evolution as a public biotech company. Professionally, Gérard Soula’s legacy is tied to the creation of a French biotechnology company that has built a strong position in metabolic disease research. He helped transform a family scientific project into a listed company with a recognized technological platform and a clear strategic identity. His career at Adocia illustrates a rare combination of scientific credibility, entrepreneurial drive, and board-level oversight, making him an important reference point in French corporate biotechnology governance.